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1 The present study describes the eect of low frequency, low energy, pulsing electromagnetic ®elds
(PEMFs) on A2A adenosine receptors in human neutrophils.
2 Saturation experiments performed using a high anity adenosine antagonist [
3H]-ZM 241385
revealed a single class of binding sites in control and in PEMF-treated human neutrophils with
similar anity (KD=1.05+0.10 and 1.08+0.12 nM, respectively). Furthermore, after 1 h of
exposure to PEMFs the receptor density was statistically increased (P50.01) (Bmax =126+10
and 215+15 fmol mg
71 protein, respectively).
3 The eect of PEMFs was speci®c to the A2A adenosine receptors. This eect was also intensity,
time and temperature dependent.
4 In the adenylyl cyclase assays the A2A receptor agonists, HE-NECA and NECA, increased cyclic
AMP accumulation in untreated human neutrophils with an EC50 value of 43 (40±47) and 255
(228±284) nM, respectively. The capability of HE-NECA and NECA to stimulate cyclic AMP levels
in human neutrophils was increased (P50.01) after exposure to PEMFs with an EC50 value of
10(8±13) and 61(52±71) nM, respectively.
5 In the superoxide anion (O2
7) production assays HE-NECA and NECA inhibited the generation
of O2
7 in untreated human neutrophils, with an EC50 value of 3.6(3.1±4.2) and of 23(20±27) nM,
respectively. Moreover, in PEMF-treated human neutrophils, the same compounds show an EC50
value of 1.6(1.2±2.1) and of 6.0(4.7±7.5) nM respectively.
6 These results indicate the presence of signi®cant alterations in the expression and in the
functionality of adenosine A2A receptors in human neutrophils treated with PEMFs.
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Introduction
Adenosine, an endogenous modulator of a wide range of
biological functions, interacts with at least four cell surface
subtypes classi®ed as A1,A 2A,A 2B and A3 receptors which are
coupled to G proteins (Fredholm et al., 2000; Klotz, 2000). In
the peripheral system, A2A receptors are present on numerous
tissues including neutrophils, monocytes, macrophages, lym-
phocytes, platelets, mast cells and show simi-larities to those
obtained in CHO cells transfected with the human A2A receptor
(Gessi et al., 2000; Fredholm et al., 2001). Activation of A2A
receptors seems to be associated with inhibition of tumour
necrosis factor (TNF)-a, IL-6, IL-8 and elastase release by
activated mononuclear phagocytes (Elenkov et al., 2000;
Tsuruta et al., 2000). Recently, it has been revealed that an
A2A adenosine receptor-dependent mechanism exists by which
aspirin retains its anti-in¯ammatory activity (Cronstein et al.,
1999). It has also been demonstrated that anti-in¯ammatory
eects of methotrexate are mediated via adenosine receptors
(Montesinos et al., 2000). Moreover, it is generally accepted
that adenosine stimulates accumulation of intracellular cyclic
AMP, which acts as a second messenger to alter cellular
function (Sullivan & Linden, 1998). A good correlation was
found between cyclic AMP accumulation data andinhibition of
superoxide anion generation by adenosine receptor agonists
studied suggesting that the cyclic AMP could be involved in the
action of A2A receptors to inhibit superoxide anion formation
(Varani et al., 1998).
Interest has grown concerning the exposure to extremely
low frequency electric and magnetic ®elds (PEMFs) originat-
ing from power lines and from diagnostic apparatus (Bersani
et al., 1997). The osteo-inductive activity of PEMFs and their
action on the local in¯ammation (Cane Á et al., 1993; De
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phases of bone repair (Matsumoto et al., 2000; Satter et al.,
1999) is well established. A careful investigation of possible
genotoxic eects of PEMFs has suggested that the exposure
does not induce any chromosomal alteration such as
breakages, translocations or inversion (Cadossi et al., 1992).
Recently, it has been observed that PEMFs modulate the
neurite outgrowth in vitro and nerve regeneration in vivo
(Shah et al., 2001). Several hypotheses have been proposed to
explain the in¯uence of PEMFs on living systems, and most
of them share the common assumption that the cell
membrane is most likely the target for ®eld interaction
(Bonhomme-Faivre et al., 1998). It has been proposed that
electromagnetic exposure may aect ligand binding with
membrane receptors and can also aect the membrane
protein distribution (Chiabrera et al., 2000).
The present paper describes, for the ®rst time, the eect of
PEMFs on A2A adenosine receptors in human neutrophils.
Saturation binding experiments performed using a high
anity radioligand antagonist, [
3H]-ZM 241385, revealed a
signi®cant increase of the A2A adenosine receptor density in
neutrophils treated with PEMFs. The eect of PEMFs was
speci®c to the A2A adenosine receptors, intensity, time and
temperature dependent. Finally, a signi®cant increase of the
A2A adenosine receptor signalling in the adenylyl cyclase
assay and in the capability by adenosine agonists to inhibit
the generation of superoxide anion production has been
reported.
Methods
Field characteristics
The neutrophils or neutrophil membranes were exposed to a
PEMFs generated by a pair of rectangular horizontal coils
(14623 cm) each made of 1400 turns of copper wire; coils
were powered by a pulse generator (IGEA, Italy). The
general characteristics of the ®eld were reported in previous
work (Cadossi et al., 1992). Brie¯y, the exposure system has
three components: (1) the signal generator, which produces
the input voltage of pulses at 75 Hz; (2) the ampli®er, which
produces the electrical voltage output (200 V) supplying coils;
(3) the coils which produce the magnetic ®eld varying from
0.2 to 3.5 mTesla (mT) to evaluate the eect of intensity on
binding parameters. The induced electric ®eld in air is
0.04 mVcm
71.
The neutrophils or neutrophil membranes were PEMF-
treated or untreated for dierent incubation times (30, 45, 60,
90 and 120 min). The temperature, continuously monitored
by a thermoresistor within the incubator, was constant
through the exposure time and exactly maintained during
the binding and functional experiments.
Preparation of cell suspensions
The cell preparation were isolated from heparin-treated
peripheral blood (100±200 ml) provided by the Blood Bank
of the University Hospital of Ferrara. Blood was donated by
healthy human volunteers after written informed consent for
research. Human neutrophils were prepared according to the
procedure of Varani et al. (1998). Blood was supplemented
with 20 ml of a solution consisting of 6% by weight dextran
T500. After gentle mixing, erythrocytes were allowed to settle
down at 208C for 60 min, and the turbid upper layer
containing leukocytes was carefully removed and placed into
centrifuge tube. Leukocytes were pelleted by centrifugation at
208C for 10 min at 1006g. Remaining erythrocytes were
lysed by suspending the cell pellet in 10 ml of distilled water
at 48C under gentle agitation. After 30 s, isotonicity was
restored by adding 3 ml of a solution containing 0.6 M NaCl.
Cells were pelletted by centrifugation at 208C for 5 min at
2506g, suspended in 10 ml of the Krebs±Ringer phosphate
buer and layered into 10 ml of Fycoll-Hypaque. Neutro-
phils were sedimented by centrifugation at 208C for 20 min at
2506g. This procedure allowed studies of cell suspensions
containing 98+2% neutrophils with few contaminating red
blood cells or platelets. This cell suspension was used for
measurement of cyclic AMP and superoxide anion produc-
tion experiments.
Preparation of neutrophil membranes
Human neutrophils were suspended in 50 mM tris HCl pH
7.4 containing 10 mM MgCl2 and centrifuged at 12,0006g
for 15 min at 48C. The supernatant was discarded and the
pellet resuspended in 10 ml of 50 mM Tris HCl and
centrifuged at 12,0006g for 15 min. The resulting pellet
was suspended again at a concentration of 100±150 mg
protein 100 ml
71 and this homogenate was used for the assay
of [
3H]-ZM 241385 binding. The protein concentration was
determined according to a Bio Rad method (Bradford, 1976)
with bovine albumin as reference standard.
[
3H]-ZM 241385 binding assay in the neutrophil
membranes
Binding assays were carried out according to Varani et al.
(1997). In kinetic studies, neutrophil membranes (PEMF-
treated or untreated) were incubated with 1 nM [
3H]-ZM
241385 in a thermostatic bath at 48C. For the measurement
of the association rate, the reaction was terminated at time
points ranging from 2±120 min by rapid ®ltration under
vacuum, followed by washing with 5 ml ice-cold buer four
times. For the measurement of the dissociation rate,
membranes were pre-incubated with [
3H]-ZM 241385 at 48C
for 120 min and after the addition of 1 mM ZM 241385 the
reaction was terminated at time points ranging from 2 to
60 min. In saturation studies, neutrophil membranes (PEMF-
treated or untreated) were incubated with 8±10 dierent
concentrations of [
3H]-ZM 241385 ranging from 0.05 to
10 nM in a total volume of 250 ml containing 50 mM Tris HCl
buer, 10 mM MgCl2, pH 7.4. Saturation experiments of
[
3H]-ZM 241385 binding to the human PEMF-treated or
untreated neutrophil membranes were performed using
dierent conditions to evaluate their eect on binding
parameters: (i) at dierent incubation times as 30, 45, 60,
90 or 120 min at 48C; (ii) at dierent intensity of the
magnetic ®elds as 0.2, 0.5, 1, 1.5, 2.5, 3.5 mT; (iii) at dierent
temperatures as 0, 10, 15, 20, 25 and 308C carried out at
various incubation time from 60 min at 08C to 20 min at
258C according to the results of previous time course
experiments. In competition experiments, carried out to
determine the IC50 values, 1 nM of [
3H]-ZM 241385, 100 ml
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71) and at
least 6±8 dierent concentrations of HE-NECA or NECA as
typical adenosine receptor agonists were incubated at 48C for
60 min. Analogous experiments were performed in the
presence of 100 mM GTP. Non speci®c binding was de®ned
as binding in the presence of 1 mM ZM 241385 or 1 mM SCH
58261 and was about 30% (35%) of total binding. Bound
and free radioactivity were separated by rapid ®ltration
through Whatman GF/B ®lters with a Micro-Mate 196 cell
Harvester (Packard Instrument, Co). The ®lter bound
radioactivity was counted using a microplate scintillation
counter (Top Count, Meriden, CT, U.S.A.) at an eciency of
57% with a Micro-Scint 20.
Measurement of cyclic AMP levels in human neutrophils
PEMF-treated or untreated human neutrophils
(10
6 cells ml
71) were suspended in 0.5 ml incubation mixture
Krebs Ringer phosphate buer, containing 1.0 IU adenosine
deaminase ml
71 and 0.5 mM Ro 20-1724 as phosphodiester-
ase inhibitor and preincubated for 10 min in a shaking bath
at 378C. Then forskolin 1 mM, HE-NECA or NECA at
dierent concentrations (1 nM±10mM) were added to the
mixture and the incubation continued for a further 5 min.
The eect of typical selective A2A antagonist, SCH 58261
(1 mM) was determined by antagonism of the HE-NECA or
NECA (100 nM)-induced stimulation of cyclic AMP levels.
The reaction was terminated by the addition of cold 6%
trichloroacetic acid (TCA). The TCA suspension was
centrifuged at 20006g for 10 min at 48C and the supernatant
was extracted four times with water saturated diethyl ether.
The ®nal aqueous solution was tested for cyclic AMP levels
by a competition protein binding assay carried out according
to the method of Varani et al. (1996). Samples of cyclic AMP
standards (0±10 pmol) were added to each test tube
containing trizma base 0.1 M, aminophylline 8.0 mM, mer-
captoethanol 6.0 mM, pH 7.4 and [
3H]-cyclic AMP in a total
volume of 0.5 ml. The binding protein, previously prepared
from beef adrenals, was added to the samples and incubated
at 48C for 150 min. At the end of the incubation time and
after the addition of charcoal the samples were centrifuged at
20006g for 10 min. The clear supernatant was mixed with
4 ml of Atomlight and counted in a LS-1800 Beckman
scintillation counter.
Superoxide anion production in human neutrophils
O2
7 production was measured by the superoxide dismutase
(0.5 mg ml
71)-inhibitable reduction of ferricytochrome c
modi®ed for microplate-based assays (Varani et al., 1998).
The tests were carried out in a ®nal volume of 200 ml
containing 4610
5 neutrophils, 100 nM of cytochrome c and
Krebs Ringer phosphate buer. At zero time 1 mM fMLF was
added, and the plates were incubated in a microplate reader
(Ceres 900, Bio-TeK Instruments, VT, U.S.A.) with the
compartment T set at 378C. Absorbance was recorded at
wavelengths of 550 and 468 nm and the dierences in
absorbance at the two wavelengths were used to calculate
nmoles of O2
7 produced, using a molar extinction coecient
for cytochrome c of 18.5 mM
71 cm
71. Neutrophils were
preincubated in the presence of 5 mgm l
71 cytochalasin B
for 5 min prior to activation by fMLF. The net nmoles of
O2
7 released were calculated from the formula: nmoles
released by stimulated neutrophils minus nmoles released by
resting neutrophils alone. Inhibitory activity was determined
by measuring the A2A agonist's ability to inhibit O2
7
production as activated by fMLF. The percentage of activity
was obtained by comparing the nmoles of O2
7 in the absence
(100%) and in the presence of HE-NECA or NECA at
dierent concentrations (1 nM±1mM). The eect of typical
selective A2A antagonist, SCH 58261 (1 mM) was determined
by antagonism of the HE-NECA or NECA at the
concentration of 100 nM.
PEMF response specificity
Binding to a2 adrenergic receptors was carried out with [
3H]-
UK 14304 (0.2±10 nM) on human neutrophils in a 50 mM
Tris HCl buer pH 7.4, containing MgCl2 10 mM for 60 min
at 258C. Non-speci®c binding was determined with 1 mM of
UK 14304 (Zaccaria et al., 1997). Binding to a2 adrenergic
receptors was carried out with [
3H]-CGP 12177 (0.1±10 nM)
on human neutrophils in a 50 mM Tris HCl buer pH 7.4,
containing MgCl2 10 mM for 60 min at 258C. Non-speci®c
binding was determined with 10 mM of CGP 12177 (Borea et
al., 1992). Binding to a- and k-opioid receptors were
performed on human neutrophils with [
3H]-DAMGO and
[
3H]-U69593 in a 50 mM Tris HCl buer pH 7.4 for 60 min at
258C. Non-speci®c binding was determined with 100 mM of
bremazocine (Varani et al., 1999). The eects of isoproterenol
(1 nM±10mM) on stimulation of adenylate cyclase activity
and on superoxide anion production were evaluated to verify
if PEMFs involve the functionality of another G protein
coupled receptor.
Data analysis
All binding studies (kinetic, saturation and competition
experiments) were analysed with the program LIGAND
(Munson & Rodbard, 1980) which performs weighted, non
linear, least squares curve ®tting program. The EC50 and IC50
values obtained in cyclic AMP and superoxide anion
production assays were calculated by non linear regression
analysis using the equation for a sigmoid concentration-
response curve (GraphPAD Prism, San Diego, CA, U.S.A.).
EC50 values were expressed as geometric means with 95%
con®dence intervals and all other data were expressed as the
arithmetic mean+s.e.mean. Analysis of data was done with
Student's t-test (unpaired analysis). Dierences were con-
sidered signi®cant at a value of P50.01.
Materials
Dextran and Ficoll-Paque were purchased from Pharmacia
(Uppsala, Sweden). [
3H]-ZM 241385 (speci®c activity 17
Ci mmol
71) was obtained by Tocris Cookson Ltd (North-
point Fourth Way, Bristol, U.K.). HE-NECA, NECA,
cytochrome c, fMLF, Ro 20-1724, cyclic AMP, bovine serum
albumin, cytochalasin B and adenosine deaminase were
obtained from Sigma-RBI (St. Louis, MO, U.S.A.). SCH
58261 was a kind gift of Dr Ennio Ongini, Schering Plough
Research Institute, Milan, Italy. [
3H]-cyclic AMP (speci®c
activity 21 Ci mmol
71), [
3H]DAMGO (speci®c activity
65 Ci mmol
71), [
3H]U69593 (speci®c activity 44 Ci mmol
71),
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3H]-UK 14304 (speci®c activity 62 Ci mmol
71), [
3H]-
CGP12177 (speci®c activity 43 Ci mmol
71) were obtained
by NEN Research Products (Boston, MA, U.S.A.). All other
reagents were of analytical grade and obtained from
commercial sources.
Results
Kinetic studies
Kinetic studies (n=3) showed that [
3H]-ZM 241385 binding
reached equilibrium after approximately 20 min and was stable
for at least 3 h in the absence (Figure 1A) or in the presence of
PEMF treatment (Figure 2A). [
3H]-ZM 241385 binding was
rapidly reversed by the addition of 1 mM ZM 241385 in the
absence (Figure 1B) or in the presence of PEMF treatment
(Figure 2B). Computer analysis revealed that both association
and dissociation data ®t a two site was not signi®cantly better
than a one-component model (P50.05) in untreated human
neutrophils with the following rate constants:
Kobs=0.100+0.005 min
71 and K71=0.055+0.003 min
71.
From the K+1=0.045+0.002 min
71 nM
71 and the K71 values
gave a kinetic dissociation constant KD of 1.22+0.12 nM.I n
human neutrophils treated with PEMFs the kinetic data are:
Kobs=0.103+0.005 min
71, K71=0.059+0.002 min
71 and
K+1=0.044+0.003 min
71 nM
71. Consequently, the apparent
equilibrium dissociation constant (KD) was calculated showing
a value of 1.33+0.15 nM.
Saturation binding assays to A2A adenosine receptor
A series of experiments were carried out to determine the eect
of PEMFs on the binding parameters of A2A adenosine
receptors. Table 1 reports anity (Kd,n M) and density (Bmax,
fmol mg
71 protein) of A2A adenosine receptors on human
neutrophil membranes exposed to dierent PEMF incubation
times (30, 45, 60, 90, 120 min). The incubation time does not
modify the anity values of both PEMF-treated or untreated
neutrophils. On the contrary the Bmax values of A2A adenosine
receptors present in human neutrophils are altered after 30 min
Figure 1 (A) Kinetics of 1 nM [
3H]-ZM 241385 binding to A2A
adenosine receptors in untreated human neutrophil membranes with
association curves representative of a single experiment. Inset, ®rst-
order plots of [
3H]-ZM 241385 binding. Be represents the amount of
[
3H]-ZM 241385 bound at equilibrium and B represents the amount
of [
3H]-ZM 241385 bound at each time. Association rate constant
was K+1=0.045+0.002 min
71 nM
71. (B) Kinetics of 1 nM [
3H]-ZM
241385 binding to human A2A adenosine receptors with dissociation
curves representative of a single experiment. Inset, ®rst-order plots of
[
3H]-ZM 241385 binding. Dissociation rate constant was:
K71=0.055+0.003 min
71.
Figure 2 (A) Kinetics of 1 nM [
3H]-ZM 241385 binding to A2A
adenosine receptors in PEMF-treated human neutrophil membranes
with association curves representative of a single experiment. Inset,
®rst-order plots of [
3H]-ZM 241385 binding. Be represents the
amount of [
3H]-ZM 241385 bound at equilibrium and B represents
the amount of [
3H]-ZM 241385 bound at each time. Association rate
constant was K+1=0.044+0.003 min
71 nM
71. (B) Kinetics of 1 nM
[
3H]-ZM 241385 binding to human A2A adenosine receptors with
dissociation curves representative of a single experiment. Inset, ®rst-
order plots of [
3H]-ZM 241385 binding. Dissociation rate constant
was: K71=0.059+0.002 min
71.
British Journal of Pharmacology vol 136 (1)
Effect of PEMFs on A2A adenosine receptors K. Varani et al 60of PEMF treatment and remain to a steady value also for the
other incubation times. A series of experiments were performed
to evaluate the relationship between intensity of PEMFs and
changes in the binding parameters of [
3H]-ZM 241385 to A2A
adenosine receptors by studying the potential eect of various
intensities of PEMFs ranging from 0.2 to 3.5 mT. For each
intensity of PEMF, saturation curves of A2A adenosine
receptors were performed and corresponding binding para-
meters were determined. No eect was observed under 0.5 mT
and the maximum eect appeared from 1 to 3.5 mT reaching a
stable plateau. Table 2 reports the anity (KD,n M) and density
(Bmax, fmol mg
71 protein) of A2A adenosine receptors linked to
dierent intensity of PEMFs. Figures 3 and 4 report a
saturation curve of [
3H]-ZM 241385 binding to A2A adenosine
receptors in human neutrophil untreated or treated for 1 h with
PEMFs, respectively. The linearity of the Scatchard plot in the
inset is indicative of the presence of a single class of binding
sites with a KD value of 1.05+0.10 nM and Bmax value of
126+10 fmol mg
71 protein in human neutrophils untreated
(n=4). Moreover, in human neutrophils treated with PEMFs
the KD value was 1.08+0.12 nM and Bmax value was
215+15 fmol mg
71 protein (n=4). Temperature dependence
were evaluated through saturation experiments performed at 0,
10, 15, 25 and 308C and the Scatchard plots are linear in the
concentration range investigated. In untreated neutrophils KD
values of [
3H]-ZM 241385 range from 1.04+0.09 nM (08C) to
4.52+0.42 nM (308C). However, Bmax values are independent
of temperature (mean value being 112+14 fmol mg
71 protein).
Also in PEMF-treated neutrophils KD values of [
3H]-ZM
241385 range from 1.06+0.10 nM (08C) to 4.84+0.50 nM
(308C), whereas Bmax values appear independent of tempera-
ture (mean value being 211+16 fmol mg
71 protein).
Competition studies to A2A adenosine receptor
Figure 5A,B shows the competition curves of HE-NECA and
NECA in untreated or PEMF-treated human neutrophils,
respectively. In untreated human neutrophils HE-NECA and
NECA show a Ki value of 9.6 (6.6±14.2) nM (Figure 5A) and
25 (20±31) nM (Figure 5B), respectively (n=4). In parallel
studies, the anity of HE-NECA and NECA in human
neutrophils treated with PEMFs, present a Ki values of 8.8
(7.6±10.3) nM (Figure 5A) and 23 (19±27) nM (Figure 5B),
respectively (n=4). To assess adenosine A2A receptor-G
protein interactions, inhibition experiments were performed
also in the presence of 100 mM GTP. The presence of GTP
did not modify the anity of HE-NECA and NECA that
show in untreated and PEMF-treated human neutrophils
similar Ki values (Ki=9.2 (8.1±10.9) nM and 25 (20±29) nM,
respectively).
Cyclic AMP assays
The A2A adenosine receptor is coupled to stimulation of
adenylyl cyclase via Gs stimulatory proteins, which leads to
increases of cyclic AMP formation. We evaluated the
sensitivity of adenylyl cyclase to pharmacological agents that
are known to speci®cally activate this eector system.
Untreated or PEMF-treated neutrophils did not reveal
changes of basal enzyme activity and of the response of
adenylyl cyclase to the direct activator forskolin used in the
absence or in the presence of the cyclic AMP-dependent
phosphodiesterase inhibitor, Ro 20-1724 (Table 3). Finally,
we evaluated the stimulatory eect of typical A2A adenosine
agonists on the adenylyl cyclase activity. When the adenosine
agonists NECA or HE-NECA were incubated with PEMF-
treated or untreated neutrophils, an ampli®cation of adenylyl
cyclase response was detected revealing a signi®cant increase
Table 1 Binding parameters of the A2A adenosine receptor
antagonist [
3H]-ZM 241385 in human neutrophil membranes
at dierent incubation times
Incubation KD Bmax
time (min) Treatment (nM) (fmol mg
71 protein)
30 Control 0.96+0.09 118+11
PEMF 0.98+0.10 205+13*
45 Control 1.00+0.14 121+12
PEMF 1.03+0.11 218+16*
60 Control 1.05+0.10 126+10
PEMF 1.08+0.12 215+15*
90 Control 0.99+0.13 115+14
PEMF 1.02+0.15 225+18*
120 Control 1.08+0.16 112+15
PEMF 1.15+0.19 220+13*
Each value represented the mean+s.e.m. of three indepen-
dent experiments performed in duplicate. Analysis was by
Student's t-test. *P50.01 vs control.
Table 2 Relationship between PEMF intensity and binding
parameters of the A2A adenosine receptor antagonist [
3H]-
ZM 241385 in human neutrophil membranes
PEMF intensity KD Bmax
(mTesla) (nM) (fmol mg
71 protein)
0.2 1.05+0.10 126+10
0.5 1.06+0.09 138+15
1 1.03+0.11 185+16*
1.5 1.11+0.15 210+14**
2.5 1.08+0.12 215+15**
3.5 1.15+0.19 218+13**
Each value represented the mean+s.e.m. of three indepen-
dent experiments performed in duplicate. Analysis was by
Student's t-test, *P50.05 vs control; **P50.01 vs control.
Figure 3 Saturation of [
3H]-ZM 241385 binding to A2A adenosine
receptors on untreated neutrophil membranes. The KD value was
1.05+0.10 nM and the Bmax value was 126+10 fmol mg
71 protein.
Experiments were performed as described in Methods. Values are the
means and vertical lines s.e.mean of four separate experiments
performed in triplicate. In the inset the Scatchard plot of the same
data is shown.
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manner. As shown in Figure 6 the log dose-response curve
for HE-NECA and NECA, typical adenosine receptor
agonists, in control and PEMF-exposed human neutrophils
revealed an increase in cyclic AMP levels. HE-NECA
determines an increase of stimulation of cyclic AMP levels
in untreated or PEMF-treated human neutrophils with EC50
values of 43 (40±47) nM and 10 (8±13) nM, respectively
(Figure 6A). NECA elicited a stimulation of cyclic AMP
levels in untreated or PEMF-treated human neutrophils with
EC50 values of 255 (228±284) nM and 61 (52±71) nM,
respectively (Figure 6B). The selective A2A SCH 58261
(1 mM) totally inhibited the rise in cyclic AMP levels induced
by NECA (100 nM) or by HE-NECA (10 nM) suggesting that
the stimulatory eect was essentially A2A mediated (Table 3).
Superoxide anion production
The next step addressed in our study was to investigate the
eect of the A2A adenosine receptors to inhibit the superoxide
anion generation. In particular, the eect of typical A2A
adenosine agonists HE-NECA or NECA on O2
7 generation
by fMLF-stimulated neutrophils was evaluated. In untreated
neutrophils these compounds were able to inhibit the
generation of O2
7 stimulated by fMLF (1 mM), in a dose-
dependent manner, showing an EC50 value of 3.6 (3.1±
4.2) nM (Figure 7A) and 23 (20±27) nM (Figure 7B),
respectively. Moreover, in PEMF-treated human neutrophils
HE-NECA and NECA showed an EC50 value of 1.6 (1.2±
2.1) nM (Figure 7A) and 6.0 (4.7±7.5) nM (Figure 7B),
respectively. HE-NECA and NECA (100 nM) mediated
inhibitory eects which were completely blocked by using
of the selective A2A adenosine antagonist, SCH 58261, at the
®nal concentration of 1 mM. Since the A2A adenosine receptor
is coupled to stimulation of adenylyl cyclase via Gs
Figure 4 Saturation of [
3H]-ZM 241385 binding to A2A adenosine
receptors on PEMF-treated human neutrophil membranes. The KD
value was 1.08+0.12 nM and the Bmax value was 215+15 fmol mg
71
protein. Experiments were performed as described in Methods.
Values are the means and vertical lines s.e.mean of four separate
experiments performed in triplicate. In the inset the Scatchard plot of
the same data is shown.
Figure 5 Competition experiments of speci®c [
3H]-ZM 241385
binding to A2A adenosine receptors of HE-NECA (A) and NECA
(B) in untreated and PEMF-treated human neutrophil membranes.
Curves are representative of a single experiment from a series of four
experiments. Competition experiments were performed as described
in Methods.
Figure 6 Stimulation of cyclic AMP levels in untreated and PEMF-
treated human neutrophils by HE-NECA (A) and NECA (B). Curves
are representative of a single experiment from a series of four
independent experiments.
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analysed the sensitivity of adenylyl cyclase to agents that are
known to speci®cally activate this eector system.
PEMF response specificity
To verify that the eect of PEMF is strictly correlated to
the presence of the adenosine receptors, we studied other
types of membrane receptors coupled to G proteins. The
expression of a2, b2 adrenergic and m and k opioid
receptors in PEMF-treated and untreated human neutro-
phils was determined performing saturation binding experi-
ments using [
3H]-UK14304, [
3H]-CGP12177, [
3H]-DAMGO
and [
3H]-U69593, respectively. A single saturable binding
site was detected for all type of receptors. Saturation of
[
3H]-UK14304 binding shows a KD value of 2.12+0.04 nM
and a Bmax value of 34+2 fmol mg
71 protein. [
3H]-
CGP12177 exhibits high anity for a2 receptors with a
KD value of 0.16+0.02 nM and Bmax value of
9.0+0.5 fmol mg
71 protein. [
3H]-DAMGO and [
3H]-
U69593 label a and k opioid receptors and reveal a KD
value of 2.29+0.11 and 0.80+0.08 nM, and Bmax value of
4.7+0.2 and 4.6+0.2 fmol mg
71 protein, respectively.
Anity of the dierent G protein coupled receptors for
their ligand as measured by the dissociation constant (KD)
are comprised in the lower nM range (from 0.16 to
2.29 nM). The receptor binding capacity, as measured by
Bmax, is not abundant and varies from 4 to 34 fmol mg
71
protein. None of these bindings were signi®cantly aected
by PEMF-treatment at 2.5 mT, an intensity that promotes
an up regulation of A2A adenosine receptors. In addiction,
we analysed the speci®city of PEMF in functional studies
as cyclic AMP and superoxide anion production assays.
Isoproterenol (1 nM±10mM) acting via b adrenoceptor, is
able to stimulate adenylate cyclase activity and to determine
an increase of cyclic AMP levels showing an EC50 value of
212 (194±246) nM and was not in¯uenced by the PEMFs
treatment (EC50=224 (202±255) nM). Moreover, isoproter-
enol inhibits fMLP-induced superoxide anion generation
showing an IC50 value of 82 (74±96) nM strictly similar to
that obtained in the presence of PEMFs treatment
(IC50=76 (68±85) nM).
Discussion
It is well known that a biological system exposed to a
physical stimulus is able to detect its presence and to modify
its own biological activity depending on the characteristics of
the applied stimulus such as mechanic, electric or magnetic.
The cell structure, able to receive the applied energy, has been
identi®ed to be cell membrane (Cadossi et al., 1992). In the
past, it has been veri®ed that electric or magnetic ®elds can
aect membrane functions not only by a local eect on ion
¯uxes or ligand binding, but also by altering the distribution
and/or the aggregation of the intramembrane protein
(Bersani et al., 1997). It is known that such proteins include
a variety of dierent specialised molecules, such as receptors,
enzymes, ion channels, integrins that are essential for many
fundamental functions mainly related to signal transduction
and cell adhesion. In particular, the in¯uence of radio-
frequency electromagnetic exposure on ligand binding to
hydrophobic receptor proteins is a plausible early event of the
interaction mechanism (Chiabrera et al., 2000). Collateral
studies of magnetic or electric ®elds reveal a modulation in
Table 3 Basal and forskolin stimulated cyclic AMP
formation in human neutrophils. Stimulation of cyclic
AMP levels by NECA and HE-NECA and antagonism by
SCH 58261
Control PEMF treatment
(pmoles cyclic (pmoles cyclic
AMP 10
5 cells
71) AMP 10
5 cells
71)
Basal levels 18+22 0 +4
Forskolin (1 mM)7 2 +87 5 +9
Forskolin (1 mM)+
Ro 201724 (0.5 mM)7 8 +88 2 +8
NECA (100 nM)3 5 +36 8 +6*
HE-NECA (10 nM)3 2 +36 2 +5*
NECA (100 nM)+
SCH 58261 (1 mM)2 0 +21 9 +2
HE-NECA (10 nM)+
SCH 58261 (1 mM)1 8 +22 0 +3
Formation of cyclic AMP was detected in the absence of
stimuli (basal levels) and upon stimulation with forskolin
and forskolin+Ro 201724. Cyclic AMP levels were also
evaluated using 100 nM NECA and 10 nM HE-NECA in the
presence of a typical selective antagonist SCH 58261 (1 mM).
Analysis was by Student's t-test, *P50.01 vs NECA and
HE-NECA stimulated cyclic AMP formation in control
human neutrophils.
Figure 7 Eect of HE-NECA (A) and NECA (B) on O2
7
production induced by FMLF in untreated and PEMF-treated
human neutrophils. Curves are representative of a single experiment
from a series of four independent experiments.
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receptor sites in the membrane surface (Massot et al., 2000).
Static and time varying magnetic ®elds have been shown to
alter animal and human behaviour, such as directional
orientation learning, pain perception (nociception or analge-
sia) and anxiety-related behaviours (Thomas et al., 2001).
Recently, it has also been demonstrated that PEMFs mediate
the modulation of gene transcription suggesting new
perspectives in the use of electromagnetic energy (Ventura
et al., 2000). Nevertheless, evidence is now accumulating that
PEMFs may alter human cardiac rhythm and that chronic
exposure to these ®elds may enhance during surgery,
transplantation or heart attack in humans (Di Carlo et al.,
1999; 2001). The predominant eect of PEMF is also shown
on the dierent phases of bone repair and have a positive
eect on the repair process (Cane Á et al., 1993; Satter et al.,
1999; Matsumoto et al., 2000). The stimulation of repair
processes in clinical practice using the eectiveness of PEMF
stimulation for enhancement of bone healing has been
reported and accepted (Yanemori et al., 1996; Satter et al.,
1999; Saxena et al., 2000). It is worth noting that the whole
of these early eects of physical stimuli is able to trigger a
more complex biologic response such as cell proliferation that
represents the basic eect to explain some relevant clinical
results (Sollazzo et al., 1997; De Mattei et al., 1999; Shah et
al., 2001). Dierent exposure of PEMF induces an increase in
the proliferation of human articular chondrocytes suggesting
an important role also in cartilagine repair (Pezzetti et al.,
1999). In earlier studies, it has been veri®ed that PEMFs
induce programmed cell death in cultured T cells and
determine a decreased T-cell proliferative capacity (Jasti et
al., 2001). Generally, it has been established that in¯amma-
tion is characterized by massive in®ltration of T lymphocytes,
neutrophils and macrophages into the damaged tissue (Gessi
et al., 2000). The available studies demonstrating the presence
of A2A adenosine receptors in human neutrophils, strongly
suggest that adenosine could play an important role in
modulating immune and in¯ammatory processes and the
activation of A2A receptors may have a relevant therapeutic
potential (Cronstein et al., 1999; Montesinos et al., 2000). It
is known that neutrophils are the most abundant white cells
in the peripheral blood and are usually the ®rst cells to arrive
at an injured or infected site. Adenosine, interacting with
speci®c receptors on the surface of neutrophils, has been
recognized as an endogenous anti-in¯ammatory agent
(Cronstein, 1994). The activation of A2A receptors in human
neutrophils aects the immune response in cancer, auto-
immune and neurodegenerative diseases and decreases
in¯ammatory reactions (Huang et al., 1997). Experimental
evidence suggests that PEMFs are able to suppress the
extravascular oedema during early in¯ammation (Lee et al.,
1997). It has also been demonstrated that the complete
healing of wounds depends on the presence of A2A adenosine
receptor agonists (Montesinos et al., 1997). In earlier studies,
it has been reported that PEMFs mediate positive eects on a
wound healing, controlling the proliferation of in¯ammatory
lymphocytes and therefore demonstrating bene®cial aects on
in¯ammatory disease (Jasti et al., 2001).
On this basis, in the present study we have evaluated the
eect of PEMFs on A2A adenosine receptors in human
neutrophils using a typical pharmacological approach based
on binding and functional characterization of this impor-
tant receptor subtype. Analysis of association and dissocia-
tion kinetic parameters of [
3H]-ZM 241385 binding in
untreated or PEMF-treated human neutrophils revealed a
KD value of 1.22 and 1.33 nM, respectively (Figures 1 and
2) of the same order of magnitude as that determined by
saturation experiments that show a KD value of 1.05 nM
and 1.08 nM, respectively (Figures 3 and 4). We have also
studied the change in the density and anity of adenosine
A2A receptors treated with dierent incubation times (30,
45, 60, 90 and 120 min) revealing also that 30 min of
treatment is able to induce an up regulation of A2A
adenosine receptors. The treatment with dierent intensity
of PEMFs reveals that lower intensity does not determine
alteration in binding parameters. On the contrary, when the
magnetic intensity is used in the range 1±3.5 mT a
signi®cant increase of adenosine A2A density is demon-
strated. The experimental results revealed a dose-response
relationship between the binding parameters of A2A
adenosine receptors and the intensity of PEMFs reaching
a stable plateau. Moreover, while KD values are widely
temperature dependent, Bmax values are quite independent
of temperature suggesting a substantial stability of the
eective receptor population at all temperatures studied.
(Borea et al., 1996; Varani et al., 1996; 1997; 1998; 2000).
Consequently the statistical dierence of Bmax values is
strictly linked to PEMF treatment. In saturation binding
experiments [
3H]-ZM 241385 labelled a single class of
recognition sites with a similar anity in both dierent
experimental conditions. On the contrary, the number of
binding sites in control or PEMF-treated human neutrophils
was increased signi®cantly (P50.01) showing a Bmax value of
126+10 fmol mg
71 protein and 215+15 fmol mg
71 protein,
respectively. These data revealed that PEMF treatment
determines a signi®cant increase of A2A adenosine receptor
density, suggesting that the upregulation can probably be due
to a translocation of this receptor subtype to the membrane
surface. The upregulation of A2A adenosine receptors cannot
probably be ascribed to the synthesis of new receptors during
the short time of PEMF treatment. In competition experi-
ments the anity of HE-NECA and NECA in the absence of
guanine nucleotides is strictly similar to those obtained in the
presence of 100 mM GTP. This result excludes a guanine
nucleotides modulation in the A2A antagonist binding such as
[
3H]-ZM 241385 even if it is known that the presence of GTP
determines dissociation of receptor G protein complexes
converting receptors from high to a low anity state. Similar
results were obtained also in other substrates as rat striatal or
human blood circulating cells using [
3H]-SCH 58261 as
radioligand (Zocchi et al., 1996; Dionisotti et al., 1997;
Varani et al., 1997; 1998). The lack of guanine nucleotide
modulation in the antagonist binding has led to the
suggestion that a tight association between the A2A adenosine
receptor and the stimulatory G protein exists (Nano et al.,
1991; Nano & Stiles, 1993). Another aim of the present
study was to investigate if the PEMF treatment determines a
dierent modulation of adenylyl cyclase activity. Our results
showed no changes of basal enzyme activity and of the
response of adenylyl cyclase to the direct activator forskolin
(1 mM) used in the absence or in the presence of cyclic AMP-
dependent phosphodiesterase inhibitor (Ro 20-1724) suggest-
ing that PEMF treatment does not modify the adenylyl
cyclase activity. Moreover, we have evaluated the capability
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and NECA to stimulate cyclic AMP levels. These compounds
showed an EC50 value in the nanomolar range, in agreement
with their anity in binding experiments (Figures 5 and 6).
In particular, HE-NECA appeared to be the most potent
compound in both dierent experimental conditions showing
an EC50 value of 43 (40±47) nM in untreated neutrophils and
10 (8±13) nM in PEMF-treated neutrophils. Similarly,
NECA showed an EC50 value of 255 (228±284) nM in
untreated neutrophils and an EC50 value of 61 (52±71) nM in
PEMF-treated neutrophils. Interestingly, the potency of HE-
NECA and NECA in the PEMF-treated neutrophils was
signi®cantly increased if compared with the untreated
neutrophils. These results suggest a selective increase of
responsiveness of the adenosine A2A receptor/adenylyl cyclase
system in the presence of PEMF treatment. To further
con®rm that the eect induced by HE-NECA or NECA on
cyclic AMP formation is due to stimulation of A2A receptor
subtype, we performed experiments in the presence of a
typical selective adenosine antagonist as SCH 58261. This
antagonist, used at the ®nal concentration of 1 mM, is able to
prevent the increase of cyclic AMP induced by the agonists
examined (100 nM) through selective stimulation of the
adenylyl cyclase via the A2A receptor. Our study of inhibition
of superoxide anion production by HE-NECA and NECA
and the block with a selective A2A antagonist (SCH 58261)
indicates that the receptor subtype involved is a typical A2A
adenosine receptor. HE-NECA and NECA show EC50 values
of 3.6 (3.1±4.2) and 23 (20±27) nM in untreated neutrophils,
respectively. In PEMF-treated human neutrophils HE-NECA
and NECA show EC50 values of 1.6 (1.2±2.1) and 6.0 (4.7±
7.5) nM (Figure 7). Binding and functional results indicate
that a 2 fold increase in Bmax is sucient to determine 4 fold
shift in EC50. We have no explanation for these dierences at
present, but it may be relevant that the functional assay was
carried out in intact cells at 378C whereas the binding assay is
performed on cell membranes incubated at lower tempera-
ture. Moreover several papers are present in literature
revealing that a strictly direct correlation between binding
and functional parameters does not always exist (Belardinelli
et al., 1996; Gessi et al., 2001). Most relevantly we observe
that the rank order of potencies of agonists and antagonists
in the binding assays is similar to that obtained in functional
assays (Varani et al., 1998; 1999; 2000). HE-NECA, an A2A
adenosine receptor agonist known to have the highest anity
for human neutrophils, appears also to be the most potent
compound in the cyclic AMP and O2
7 generation assays. A
good correlation was found in PEMF-treated human
neutrophils between cyclic AMP accumulation and inhibition
of O2
7 generation data. The evidence from this study that
HE-NECA was the most potent compound in both assays
would suggest that the mechanism involves the upregulation
of A2A adenosine receptors. It is worth noting that the
response of PEMF is receptor speci®c as shown by saturation
studies to other G protein coupled receptors. PEMFs
treatment does not modify the binding parameters of the
a2, b2 adrenergic and m, k opioid receptors. As for the b
adrenergic, moreover, the capability of isoproterenol to
stimulate adenylate cyclase and to inhibit the FMLP-super-
oxide anion generation is not modi®ed by PEMF treatment.
In summary, all these data provide evidence that PEMF
treatment evokes an upregulation of the A2A adenosine
receptors and alters the response of this receptor subtype in
human neutrophils. Moreover, PEMF treatment causes an
increase of adenylyl cyclase activity and a reduction of
superoxide anion production as a result of upregulation of
the A2A receptors located on the neutrophil surface. The
results reported here should serve as an impetus for further
investigation of the changes in the adenosine receptors and
functional alterations produced by PEMF treatment. From a
clinical point of view, a clari®cation of the potential
biological eects of electromagnetic exposure could facilitate
the development of alternative treatments or the elaboration
of novel promising therapeutic tools.
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